



Building trust – is it necessary?

- How much experience do you have with the administration of ...

- How much trust do you have in the effectiveness of ...



Source: Austrian Health Report 2022 – Health Care Professionals

Table 2: Estimated patent and exclusivity expiry dates for best-selling biologicals: humanized antibodies

Biological	Approval date*	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029+	
Abthrax (raxibacumab)	15 Oct 2014 14 Dec 2012	Oct 2024												2026				
Actemra/RoActemra (tocilizumab)	16 Jan 2009 8 Jan 2010	22 Dec 2015	23 Apr 2017*															
Aimovig (erenumab)	26 Jul 2018 17 May 2018																2029	2031
Avastin (bevacizumab)	12 Jan 2005 26 Feb 2004																22 Jan 2022	
Arzerra (ofatumumab)	19 Apr 2010 26 Oct 2009																2023	2030
Benlysta (belimumab)	13 Jul 2011 9 Mar 2011																2021	2023
Campath/Lemtrada (alemtuzumab)	12 Sep 2003 7 May 2001																7 May 2021	6 Jul 2021
Cablivi (caplacizumab)	30 Aug 2018 -																Sep 2028	
Cimzia (certolizumab pegol)	1 Oct 2009 22 Apr 2008																5 Jul 2021	13 Feb 2024
Cyramza (ramucirumab)	19 Dec 2014 21 Apr 2014																May 2023	Patent Nov 2025 / Exclusivity 2026
Cosentyx (secukinumab)	15 Jan 2015 21 Jan 2015	Data not available																
Darzalex (daratumumab)	25 May 2016 16 Nov 2015																25 May 2026	7 Feb 2025
Emgality (galcanezumab)	20 Sep 2018 27 Sep 2018																Sep 2028	Nov 2030
Entyvio (vedolizumab)	22 May 2014 20 May 2014	Data not available																
Fasenra (benralizumab)	08 Jan 2018 14 Nov 2017																Jan 2028	Nov 2027
Gazyva/Gazyvaro (obinutuzumab)	23 Jul 2014 1 Nov 2013																5 Nov 2024	Jan 2035
Hemlibra (emicizumab)	23 Feb 2018 16 Nov 2017																Feb 2028	Nov 2029
Herceptin (trastuzumab)	28 Aug 2000 25 Sep 1998	28 Jul 2014**															18 Jun 2019	
Humira (adalimumab)	8 Sep 2003 31 Dec 2002																Oct 2018	Dec 2022**
Iliaris (canakinumab)	23 Oct 2009 17 Jun 2009	Data not available																
Ilumetri (tildrakizumab)	20 Mar 2018 17 Sep 2018																Mar 2028	Sep 2030
Imfinzi (durvalumab)	21 Sep 2018 1 May 2017																Sep 2028	May 2029
Kadcyla (trastuzumab emtansine)	15 Nov 2013 22 Feb 2013																23 Jun 2020	8 Sep 2026
Keytruda (pembrolizumab)	17 Jul 2015 4 Sep 2014																13 Jun 2028	Nov 2036

Lartuvo (olaratumab)	9 Nov 2016 19 Oct 2016	Compound patent / Exclusivity Nov 2026																
Lucentis (ranibizumab)	22 Jan 2007 30 Jun 2006																2022	30 Jun 2020
Mylotarg (gemtuzumab ozogamicin)	19 Apr 2018 01 Sep 2017																Apr 2028	Sep 2029
Ocrevus (ocrelizumab)	28 Mar 2017 28 Mar 2017																Mar 2027	28 Mar 2029
Opdivo (nivolumab)	19 Jun 2015 22 Dec 2014																2 May 2026	19 Jun 2027
Perjeta (pertuzumab)	4 Mar 2013 8 Jun 2012																Mar 2023	Jun 2024
Portrazza (nectinumab)	15 Feb 2016 24 Nov 2015																Apr 2026	Compound patent 2025 / Exclusivity Nov 2027
Poteligeo (mogamulizumab)	11 Jan 2012 -																Jun 2033	Dec 2035
Prolia/Xgeva (denosumab)	26 May 2010 1 Jun 2010																25 Jun 2022#	19 Feb 2025
Repatha (evolocumab)	17 Jul 2015 27 Aug 2015																17 Jul 2025	2029
Simponi (golimumab)	1 Oct 2009 24 Apr 2009																Oct 2024	Feb 2024
Soliris (eculizumab)	20 Jun 2007 16 Mar 2007																1 May 2020	16 Mar 2021
Stelara (ustekinumab)	16 Jan 2009 25 Sep 2009																Jan 2024	Sep 2023
Synagis (palivizumab)	13 Aug 1999 19 Jun 1998																9 Aug 2015	20 Oct 2015
Takhzyro (lanadelumab)	22 Nov 2018 23 Aug 2018																Nov 2028	Exclusivity Mar 2030 / Patent Jan 2031
Taltz (ixekizumab)	25 Apr 2016 22 Mar 2016																Compound patent / Exclusivity Apr 2026	Compound patent 2026 / Exclusivity May 2028
Tecentriq (atezolizumab)	21 Sep 2017 18 May 2016																Sep 2027	May 2028
Tysabri (natalizumab)	27 Jun 2006 23 Nov 2004																Aug 2015	Mar 2015
Vectibix (panitumumab)	3 Dec 2007 27 Sep 2006																2018	8 Apr 2020
Xolair (omalizumab)	25 Oct 2005 20 Jun 2003																Aug 2017	20 Jun 2017
Yervoy (ipilimumab)	13 Jul 2011 25 Mar 2011																2021	2023
Zenapax (dadalizumab)	26 Feb 1999 10 Dec 1997	Expired 2013 Data not available																

European Union (EU) United States (US)

Source: Generics and Biosimilars Initiative Journal (GaBI Journal). 2019;8(1):24-31.

Relevance of oncologicals in health systems


Share of real 2020\$ drug spending by drug class, 1995 vs. 2020



Main causes of death, 2017


(%)

0 10 20 30 40 50 60 70 80 90 100



■ Diseases of the circulatory system ■ Cancers ■ Diseases of the respiratory system ■ Other

(!) 2016 data instead of 2017.



Source: IQVIA MIDAS; IQVIA Institute, Dec 2020

Notes: Please refer to Therapy areas on page 38 for therapy definitions. Eleven refers to the 11 chosen countries of the study; Real values are the reported nominal values adjusted for GDP deflation to report in 2020\$ (constant). U.S. differences between invoice and net spending are based on IQVIA Institute analysis included in The Use of Medicines in the U.S. See references.

Report: Drug Expenditure Dynamics 1995-2020: Understanding Medicine Spending in Context. IQVIA Institute for Human Data Science